Japan: Suntory to acquire Daiichi Sankyo Healthcare

Suntory Holdings, the Japanese beverage and food giant, has agreed to acquire the consumer health unit Daiichi Sankyo Healthcare (DSHC) from the global pharmaceutical firm Daiichi Sankyo in a deal valued at ¥246.5 billion ($1.55 billion).

Suntory, which has previously expanded its global footprint through the acquisition of major consumer beverage brand, stated the move is designed to establish a “unique and comprehensive self-care business”. The acquisition will be completed in stages, with Suntory taking an initial 30% stake on the 1st June 2026, increasing to 70% in 2027, and achieving 100% ownership by the 1st June 2029.

DSHC is a leading company in Japan’s over-the-counter pharmaceutical market, with a portfolio of brands including cold remedy Lulu, pain reliever Loxonin and skin care range Minon. According to sources, the healthcare unit also entered the sports nutrition category in 2024 via the acquisition of DNS.

“By welcoming DAIICHI SANKYO HEALTHCARE into the Suntory Group, the Group expects to expand its business across the self-care and self-medication domains”, the company claimed in a statement. Daiichi Sankyo noted the divestment would allow it to focus resources on its innovative pharmaceutical business, particularly its oncology portfolio.

Source: Suntory Holdings / Daiichi Sankyo / Fierce Pharma / Food & Drink International